Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.550
+0.010 (0.65%)
Feb 11, 2026, 1:54 PM EST - Market open
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,564,432
Market Cap
7.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| Theriva Biologics | 22 |
| SeaStar Medical Holding | 19 |
| CalciMedica | 15 |
| BioVie | 13 |
| Kiora Pharmaceuticals | 12 |
| XTL Biopharmaceuticals | 10 |
| Alzamend Neuro | 7 |
REVB News
- 16 days ago - Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Accesswire
- 19 days ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Accesswire
- 21 days ago - Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Accesswire
- 4 weeks ago - Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Accesswire
- 4 weeks ago - Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 5 weeks ago - Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Accesswire
- 2 months ago - Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting - Accesswire
- 2 months ago - Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year - Accesswire